Oncology Pipeline Database: 1-Year Subscription
Subscription to La Merie's proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major products are provided. The projects can be segmented into Territories, Product Categories and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database.
Purchase of the subscription provides a 1-year online access to the data of the Oncology Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the Oncology Pipeline Database:- New database with no historical burden
- Intuitive use
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
- Antibodies
- Cells
- DNA
- Medical Devicer / Biomaterial
- Peptide
- Protein
- Radiopharmaceutical
- RNA
- Small Molecule
- Vaccine
- Antibody-Drug Conjugates (ADC)
- Aurora Kinase Inhibitors
- Bcr-Abl and Src Kinase Inhibitors
- c-MET/HGF Inhibitors
- CD3 Antagonists
- CD19 Antagonists
- CD20 Antibodies
- CD22 Antibodies
- CD30 Antibodies
- CD40/L
- CEA Antibodies
- CHK and KSP/Eg5 Inhibitors
- CXCR and CXCL Agonists & Antagonists
- Death Receptors TRAIL-R1/2
- EGF-R Agonists and Antagonists
- EpCAM Antagonists
- G-CSF and GM-CSF
- HDAC Inhibitors
- Heat shock protein 90 (Hsp90) Inhibitors
- Hypoxia-Inducible Factor (HIF)
- IGF-1R Antagonists
- Immunocytokines
- Immunotoxins
- Integrin Antagonists
- Interferon
- Janus Kinase (JAK) Inhibitors
- MEK Inhibitors
- Novel Mitotic Kinase Inhibitors
- PARP Inhibitors
- PDGF-R Agonists and Antagonists
- PI3K-AKT-mTOR Inhibitors
- Polo-like Kinase 1 (Plk-1) Inhibitors
- Proteasome Inhibitors
- Raf Inhibitors
- Ras-Raf-MEK-ERK Inhibitors
- Selective Estrogen Receptor Modulators (SERM)
- TGF-R Agonists and Antagonists
- Thrombopoiesis Stimulating Agents (TPO)
- Toll-Like Receptor (TLR) Agonists and Antagonists
- TRAIL-R1/R2 (Death Receptors)
- VEGF and VEGF-R Agonists and Antagonists
